STAT July 18, 2024
LONDON — A Novartis executive on Thursday said “it’s too early to say” whether the company would still submit an experimental myelofibrosis drug for regulatory approval this year, amid questions about the medicine’s data profile and whether it’s sufficient for filing.
Novartis had previously said it planned to submit a marketing application for a rare bone marrow cancer drug called pelabresib to the Food and Drug Administration this year. But on...
Today's Sponsors
Today's Sponsor